未登录

C

Christine Fazenbaker

AstraZeneca

H指数:19

被引数:926

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Antitumor activity of AZD0754, a dnTGFβRII-armored STEAP2-targeted CAR-T cell therapy, in prostate cancer

JOURNAL OF CLINICAL INVESTIGATION

IF13.6

2023-11-1511

OAAI

Zanvit, Peter; van Dyk, Dewald; Fazenbaker, Christine; Mcglinchey, Kelly; Luo, Weichuan; Pezold, Jessica M.; Meekin, John; Chang, Chien-ying; Carrasco, Rosa A.; Breen, Shannon; Cheung, Crystal Sao-Fong; Endlich-Frazier, Ariel; Clark, Benjamin; Chu, Nina J.; Vantellini, Alessio; Martin, Philip L.; Hoover, Clare E.; Riley, Kenesha; Sweet, Steve M.; Chain, David; Kim, Yeoun Jin; Tu, Eric; Harder, Nathalie; Phipps, Sandrina; Damschroder, Melissa; Gilbreth, Ryan N.; Cobbold, Mark; Moody, Gordon; Bosco, Emily E.

Antitumor activity of AZD0754, a dnTGFbRII armored STEAP2 targeted CAR-T therapy, in preclinical models of prostate cancer

CANCER RESEARCH

IF16.6

2023-04-141

PRE

A Reactive Antibody Platform for One-Step Production of Antibody-Drug Conjugates through a Diels-Alder Reaction with Maleimide

BIOCONJUGATE CHEMISTRY

IF3.9

2019-08-0526

PREAI

Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer

IF7.3

2019-03-0516

OAAI

Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition

MOLECULAR CANCER THERAPEUTICS

IF5.5

2019-01-0220

OAAI

Tuning the Diels-Alder Reaction for Bioconjugation to Maleimide Drug-Linkers

调整diels-alder反应以生物缀合至马来酰亚胺药物接头

BIOCONJUGATE CHEMISTRY

IF3.9

2018-06-2259

OAAI

Synthetic lethal targeting of BRCA mutant tumors with antibody linked pyrrolobenzodiazepine dimers

CANCER RESEARCH

IF16.6

2017-07-010

PRE

Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody

JOURNAL OF BIOLOGICAL CHEMISTRY

IF3.9

2017-03-0125

OAAI

Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties

IF7.3

2016-12-1616

OAAI

Overproduction of IGF-2 drives a subset of colorectal cancer cells, which specifically respond to an anti-IGF therapeutic antibody and combination therapies

IF7.3

2016-07-1126

PREAI

MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas

MOLECULAR CANCER THERAPEUTICS

IF5.5

2014-11-0326

OAAI

Medi-573 alone or in combination with mammalian target of rapamycin inhibitors, targets the insulin-like growth factor pathway in sarcomas

CANCER RESEARCH

IF16.6

2014-10-010

PRE

EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

IF7.2

2009-09-0288

OAAI

Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib

MOLECULAR CANCER THERAPEUTICS

IF5.5

2009-08-1436

PREAI

Antibody-Dependent Cell-Mediated Cytotoxicity Effector-Enhanced EphA2 Agonist Monoclonal Antibody Demonstrates Potent Activity against Human Tumors

IF7.7

2009-06-0141

OAAI

A Human Antibody-Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo

CANCER RESEARCH

IF16.6

2008-11-14158

OAAI